A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia

Leukemia

Volumn 11, Issue 4, 1997, Pages 485-489

  Feldman, E J ^a   Seiter, K ^a   Damon, L ^b   Linker, C ^b   Rugo, H ^b   Ries, C ^b   Case Jr , D C ^c   Beer, M ^a   Ahmed, T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Medicine   (United States)

Author keywords

Acute leukemia; Elderly patients; High dose treatment; Mitoxantrone; Myeloid

Indexed keywords

CYTARABINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030900945     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400623     Document Type: Article

References (25)

1. Preisler HD, Rustum Y, Henderson ES, Bjornsson S, Creaven PJ, Higby DJ, Freeman A, Gailani S, Naeher C. Treatment of acute non-lymphocytic leukemia: use of anthracyclines, cytosine arabinoside induction therapy and comparison of maintenance regimens. Blood 1979; 53: 455-464.
2. Arlin Z, Case DC Jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990; 4: 177-183.
3. Estey E, Smith TL, Keating MJ, McCredie K, Gehan EA, Freireich E. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3: 257-263.
4. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP. High dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long term follow-up and results. J Clin Oncol 1989; 7: 1260-1267.
5. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R. Long-term outcome of high-dose cytarabine-based consolidation therapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977-2982.
6. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB, Edelstein M, Harrington DP, O'Connell MJ. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
7. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III, for the Cancer and Leukemia group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
8. Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985; 12 (Suppl. 4): 38-42.
9. Grant S, Arlin Z, Gewitz D. Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 1991; 5: 336-339.
10. Feldman EJ, Alberts D, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Pelzia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11: 2002-2009.
11. Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984; 2: 865-870.
12. Lazarus HM, Vogler WR, Burns CP, Winton EF. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group. Cancer 1989; 63: 1055-1059.
13. Dixon WJ, Massey FJ Jr. Introduction to Statistical Analysis, 4th edn. McGraw-Hill: New York, 1983.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996; 50: 163-170.
15. Machin D, Campbell MJ (eds). Statistical Tables for the Design of Clinical Trials. Blackwell Scientific Publications: Oxford, 1987, pp. 10-34, 54-59, 79-88, 132-168.
16. Petti MC, Mandelli F, Avvisati G, Covelli A, Amadori S, Liso V, Leone G, De Laurenzi A, Leoni P, Neri A, Grignani F, Torlontano G, Deriu L, Caronia F. High-dose ara-c (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA. Eur J Hematol 1989; 42: 24-31.
17. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Walker I, Browman M, Grunwald H, D'Arrigo P, Doeblin T. High-dose cytosine arabinoside as the initial treatment of poor risk patients with acute non-lymphocytic leukemia: a leukemia intergroup study. J Clin Oncol 1987; 5: 75-82.
18. Rowe JM, Andersen JW, Mazza JJ. Randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
19. Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrozek K, Bloomfield CD, Herzig GP. High dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Semin Oncol 1993; 20 (Suppl. 8): 6-12.
20. Cassileth P, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, Bennett JM, O'Connell MJ. Maintenance chemotherapy prolongs remission duration in adult nonlymphocytic leukemia. J Clin Oncol 1988; 6: 583-587.
21. Liu Yin JA, Johnson PRE, Davies JM, Flanagan NG, Gorst DW, Lewis MJ. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukemia. Br J Haematol 1991; 79: 415-420.
22. Preisler H, Davis RB, Kirschner J, Dupre E, Richards F III, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre OR. Comparison of the remission induction regimens and two postinduction strategies for the treatment of acute non-lymphocytic leukemia: a Cancer and Acute Leukemia Group B study. Blood 1987; 69: 1441-1449.
23. Marie JP, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia 1992; 6: 720-722.
24. Foa R. Does interleukin 2 have a role in the management of acute leukemia? J Clin Oncol 1993; 11: 1817-1825.
25. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgeb HF, Old LJ. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478-490.